New York, United States
HiberCell, founded in 2019 and headquartered in the United States, is a pioneering force in the Biotechnology and Health Care industries. With a focus on developing novel therapeutics, the company aims to prevent cancer relapse and metastasis. Its slogan, "Developing Novel Therapeutics to Prevent Cancer Relapse and Metastasis", emphasizes their mission.
The company's noteworthy product candidates include HC-5404 and HC-7366, targeting stress response kinases PERK and GCN2, both having completed Phase 1a clinical trials. Additionally, odetiglucan, in Phase 2, focuses on modulating the anti-tumor innate immune response. These efforts are crucial for addressing significant cancer challenges such as tumor metastasis and treatment resistance.
HiberCell secured a significant $67.40M Series B investment on May 19, 2021, backed by notable investors including Arch Venture Partners, Magnetic Ventures, Monashee Investment Management, Trinitas Capital, Huizenga Capital Management, and Bristol-Myers Squibb, underscoring investor confidence in their innovative therapies.
